About this Journal Submit a Manuscript Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 602812, 6 pages
http://dx.doi.org/10.1155/2011/602812
Clinical Study

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
2Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221 Stanford, CA 94305, USA
3Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA

Received 18 April 2011; Revised 12 June 2011; Accepted 8 July 2011

Academic Editor: Evangelia D. Razis

Copyright © 2011 Seema Nagpal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. H. Cohen, Y. L. Shen, P. Keegan, and R. Pazdur, “FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme,” Oncologist, vol. 14, no. 11, pp. 1131–1138, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. J. Vredenburgh, A. Desjardins, J. E. Herndon et al., “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4722–4729, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. Y. Kang, T. Jin, H. Elinzano, and D. Peereboom, “Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety,” Journal of Neuro-Oncology, vol. 89, no. 1, pp. 113–118, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. F. Bokstein, S. Shpigel, and D. T. Blumenthal, “Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors,” Cancer, vol. 112, no. 10, pp. 2267–2273, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. H. S. Friedman, M. D. Prados, P. Y. Wen et al., “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4733–4740, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. T. T. Batchelor, A. G. Sorensen, E. di Tomaso et al., “AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients,” Cancer Cell, vol. 11, no. 1, pp. 83–95, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. J. Verhoeff, O. van Tellingen, A. Claes et al., “Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme,” BMC Cancer, vol. 9, article 444, 2009. View at Publisher · View at Google Scholar · View at PubMed
  8. A. D. Norden, J. Drappatz, A. Muzikansky et al., “An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma,” Journal of Neuro-Oncology, vol. 92, no. 2, pp. 149–155, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. W. Wick, M. Weller, M. van den Bent, and R. Stupp, “Bevacizumab and recurrent malignant gliomas: a European perspective,” Journal of Clinical Oncology, vol. 28, no. 12, pp. e188–e189, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. M. Bredel, “Translating biological insights into clinical endpoints in neuro-oncology,” The Lancet Oncology, vol. 10, no. 10, pp. 928–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Recht, M. Glantz, M. Chamberlain, and C. C. Hsieh, “Quantitative measurement of quality outcome in malignant glioma patients using an independent living score (ILS): assessment of a retrospective cohort,” Journal of Neuro-Oncology, vol. 61, no. 2, pp. 127–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. R. Macdonald, T. L. Cascino, S. C. Schold Jr., and J. G. Cairncross, “Response criteria for phase II studies of supratentorial malignant glioma,” Journal of Clinical Oncology, vol. 8, no. 7, pp. 1277–1280, 1990. View at Scopus
  13. P. Y. Wen, D. R. Macdonald, D. A. Reardon et al., “Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1963–1972, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. Brem, S. Piantadosi, P. C. Burger, et al., “Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group,” The Lancet, vol. 345, no. 8956, pp. 1008–1012, 1995.
  15. A. D. Norden, G. S. Young, K. Setayesh et al., “Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence,” Neurology, vol. 70, no. 10, pp. 779–787, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. A. Narayana, P. Kelly, J. Golfinos et al., “Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival: clinical article,” Journal of Neurosurgery, vol. 110, no. 1, pp. 173–180, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. L. Rubenstein, J. Kim, T. Ozawa et al., “Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption,” Neoplasia, vol. 2, no. 4, pp. 306–314, 2000. View at Scopus
  18. F. M. Iwamoto, L. E. Abrey, K. Beal et al., “Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma,” Neurology, vol. 73, no. 15, pp. 1200–1206, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. C. Chamberlain and S. K. Johnston, “Salvage therapy with single agent bevacizumab for recurrent glioblastoma,” Journal of Neuro-Oncology, vol. 96, no. 2, pp. 259–269, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. N. Kreisl, L. Kim, K. Moore, et al., “Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 740–745, 2009.
  21. P. L. Nghiemphu, W. Liu, Y. Lee et al., “Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience,” Neurology, vol. 72, no. 14, pp. 1217–1222, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. H. S. Poulsen, K. Grunnet, M. Sorensen et al., “Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours,” Acta Oncologica, vol. 48, no. 1, pp. 52–58, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II et al., “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1253–1259, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. M. Zuniga, R. Torcuator, R. Jain et al., “Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan,” Journal of Neuro-Oncology, vol. 91, no. 3, pp. 329–336, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J. H. Galicich, L. A. French, and J. C. Melby, “Use of dexamethasone in treatment of cerebral edema associated with brain tumors,” The Lancet, vol. 81, pp. 46–53, 1961. View at Scopus
  27. M. R. Carlson, W. B. Pope, S. Horvath et al., “Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2,” Clinical Cancer Research, vol. 13, no. 9, pp. 2592–2598, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. D. G. Duda, T. T. Batchelor, C. G. Willett, and R. K. Jain, “VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects,” Trends in Molecular Medicine, vol. 13, no. 6, pp. 223–230, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. E. R. Gerstner, D. G. Duda, E. di Tomaso et al., “VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer,” Nature Reviews Clinical Oncology, vol. 6, no. 4, pp. 229–236, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. S. A. Grossman, X. Ye, S. Piantadosi et al., “Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States,” Clinical Cancer Research, vol. 16, no. 8, pp. 2443–2449, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus